PharmaEssentia's novel pegylation technology platform has yielded our lead product, Ropeginterferon alfa-2b, which is a novel, long-acting, mono-pegylated proline interferon with improved pharmacokinetic properties allowing once every two weeks administration offering improved tolerability and convenience. The marketing authorization for PharmaEssentia’s Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) is granted by EMA in February 2019, Taiwan in May 2020 and FDA in November 2021.

The process of pegylation of the therapeutic protein preserves its biologic activity by targeting the PEG polymer (polyethylene glycol) at a specific and defined region on the protein. Our pegylation technology platform increases protein drug’s efficacy by prolonging its circulation in blood stream. Utilizing its innovative 40K PEG and the platform with protein engineering and PEG-related chemistry, we creates novel product Ropeginterferon alfa-2b for better disease treatment.